Cancer is the world’s second biggest killer. In 2018, cancer claimed the lives of an estimated 9.6 million people. Needless to say, there is a monumental medical need for effective cancer therapies.
As the world continues to move towards a more personalised healthcare system, people are turning towards precision oncology approaches more than ever. To put it simply, how can we profile a tumour to identify targetable alterations, and most importantly, how can we use this information to have an impact in a clinical setting?
Now, with the falling cost of sequencing and our growing understanding of cancer genomics, precision oncology is fast becoming the reality of cancer care.
This webinar series will guide you through the pre-analytical steps needed to best protect your precious, finite samples for sequencing. Next, we walk you through the challenges and opportunities of sequencing in the clinical setting. Finally, we talk you through the digital insights with the challenges of NGS adoption in Hematologic oncology.
Join us as we showcase the current state of precision oncology, discuss how to overcome the current challenges and pave the way for the next era of cancer care.
From this webinar series the audience will gain:
- Insights into the standardisation of preanalytics
- An overview of the current challenges in NGS implementation for precision oncology in a clinical setting
- How NGS data interpretation for haematological malignancies can present a unique set of challenges and how to overcome them.
- An overview of the current challenges and opportunities in precision oncology
- Insights into the importance of streamlined NGS data interpretation
Webinar 1: Standardized Preanalytics: The Key for Reliable Diagnostics, Research and Biobanking
8th September – 3pm BST/ 4pm CET/ 10am ET
When patient samples are compromised, in vitro diagnostic and research results are also compromised. In this webinar, Uwe Oelmuller discusses 22 new pre-analytical global ISO/International Standards and pan-European CEN/Technical specifications introduced or under development by the EU Horizon2020 SPIDIA4P consortium via the respective ISO and CEN Committees. The discussion will include why these workflows were developed, who benefits most from implementing them and how the related External Quality Assurance (EQA) schemes as well as new technologies will also ensure quality standards are met and upheld by all stakeholders.
The SPIDIA4P project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 733112.
Uwe Oelmueller, Vice President Head of MDx Development EU Sample Technologies, QIAGEN
Abhishek Sharma, Director Global Prod. Management and Marketing PreAnalytiX, QIAGEN
Webinar 2: Overcoming the challenges of adopting NGS in clinical oncology applications
15th September 3pm BST/ 4pm CET/ 10am ET
A better understanding of the molecular events underlying cancer development and progression is critical for improvements in patient healthcare. The identification of clinically relevant or actionable biomarkers allows clinicians to overcome bottlenecks in the lab and get the most from limited sequencing capacity by streamlining the profiling of cancer-associated alterations. This webinar will discuss the relevant biomarkers in clinical research and an innovative approach to comprehensive and integrated profiling of multiple biomarkers.
Pauline Rehal, Principal Clinical Scientist, West Midlands Regional Genomics Laboratory
Lee-Anne Zinetti, Associate Director Global Commercial Marketing – Oncology, QIAGEN
Webinar 3: The challenges of NGS data interpretation and impact on patient care for hematologic malignancies
22nd September 3pm BST/ 4pm CET/ 10am ET
Genomic analysis has greatly influenced the diagnosis, classification, prognostication, and therapeutic decision-making in the clinical management of patients affected by diverse forms of hematologic malignancies.
The increased genomic evaluation of haematological malignancies has led to an increase in the rate at which mutations are characterized for clinical utility, putting enormous pressure on the molecular diagnostics laboratories responsible for providing insightful reports to their clinicians to help guide patient management.
Join us for this panel webinar where we will discuss how NGS technologies have aided clinicians in the management of hematologic cancers, in addition to discussing strategies employed to streamline the data interpretation process.
Kristen Champion, Ph.D., FACMG, Technical Director, Molecular Pathology Laboratory at MedFusion
Gregory M. Riedlinger, M.D., Ph.D., Assistant Professor of Pathology, Division of Translational Pathology. Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey
Andrew Lane, M.D., Ph.D., Associate Professor, Medical Oncology, Dana-Farber Cancer Institute
Sheryl Elkin, PhD, Chief Scientific Officer of N-of-One, QIAGEN Digital Insights
Beate Lizenburger, Director Global Product Management, Oncology, QIAGEN Digital Insights